How much funding has Amunix Pharmaceuticals raised?

Amunix Pharmaceuticals has raised $308.5M in total funding, most recently a Series D round.

Who are Amunix Pharmaceuticals's investors?

Amunix Pharmaceuticals's investors include Viking Global, Omega Funds.

Where is Amunix Pharmaceuticals headquartered?

Amunix Pharmaceuticals is headquartered in Mountain View, California, United States.

What industry is Amunix Pharmaceuticals in?

Amunix Pharmaceuticals operates in Biotech.

How many employees does Amunix Pharmaceuticals have?

Amunix Pharmaceuticals has 11-50 employees.

Amunix Pharmaceuticals

Closed

Mountain View, United States · $308.5M raised

Biotech

Headquarters: Mountain View, California
Employees: 11–50
Business Model: B2B

Total Funding: $308.5M
Last Round: $118.5M Series DJan 2025
Rounds: 3

About

Amunix Pharmaceuticals was a Mountain View, California-based immuno-oncology company developing masked T-cell engagers and protein therapeutics for solid tumor cancers using its proprietary XTEN technology platform. The company raised $73 million in 2020 and $117 million in 2021 before being acquired by Sanofi in December 2021 for approximately $1 billion upfront, with its pipeline advancing toward clinical development. Its most advanced program, AMX-818, targeted HER2-expressing solid tumors.

Summary

Amunix Pharmaceuticals is a Biotech company based in Mountain View, United States. It has raised $308.5M in total across 3 rounds, most recently a $118.5M Series D round in Jan 2025. Investors include Viking Global and Omega Funds.